The Microbiome-Gut-Peptide Axis: A Three-Way System
Microbiome-Peptide Crosstalk
863,498 antimicrobial peptides
A machine learning analysis of the global microbiome identified nearly 864,000 unique antimicrobial peptides produced by bacteria, revealing the microbiome as a massive peptide factory.
Santos-Junior et al., Cell, 2024
Santos-Junior et al., Cell, 2024
View as imageThe gut is not just a tube that digests food. It is a peptide signaling hub where trillions of bacteria, specialized hormone-producing cells, and the nervous system exchange chemical messages that regulate appetite, blood sugar, inflammation, and immune defense. The bacteria produce metabolites that trigger peptide hormone release from intestinal cells. The peptide hormones, in turn, alter gut motility, barrier function, and microbial composition. And the bacteria themselves produce hundreds of thousands of antimicrobial peptides that shape which species survive in the gut ecosystem.[6] This three-way communication system is now recognized as a central mechanism linking diet, gut health, and metabolic disease. For a detailed look at how short-chain fatty acids drive peptide hormone release, see the cluster pillar.
Key Takeaways
- Gut bacteria ferment dietary fiber into short-chain fatty acids (SCFAs) that directly stimulate GLP-1 secretion from intestinal L-cells via the FFAR2 receptor; mice lacking FFAR2 have impaired GLP-1 release and glucose tolerance[2]
- SCFAs also stimulate PYY release from the colon, with propionate being the most potent trigger in isolated colon perfusion studies[3]
- GLP-1 receptor agonists reshape gut microbiome composition, increasing beneficial species like Akkermansia muciniphila and Bacteroides while reducing pro-inflammatory taxa[1]
- Machine learning analysis of 63,410 metagenomes identified 863,498 unique antimicrobial peptides from the global microbiome, revealing bacteria as a vast source of bioactive peptides[6]
- Incretin receptor agonists directly inhibit AgRP hunger neurons in the brain, with the magnitude of neural inhibition proportional to appetite suppression[4]
- The bidirectional nature of this system suggests that microbiome composition may partially determine individual responses to GLP-1-based therapies[1]
Direction 1: Bacteria to Peptide Hormones
The most well-characterized arm of the microbiome-gut-peptide axis runs from bacterial metabolism to peptide hormone secretion. When gut bacteria ferment dietary fiber, they produce short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. These SCFAs are not inert byproducts. They are signaling molecules that act directly on hormone-producing cells in the intestinal wall.
SCFAs Trigger GLP-1 Release
Tolhurst and colleagues demonstrated the molecular mechanism in 2012.[2] Using colonic cell cultures, they showed that SCFAs stimulate glucagon-like peptide-1 (GLP-1) secretion from L-cells via two G-protein-coupled receptors: FFAR2 (GPR43) and FFAR3 (GPR41). Both receptors were enriched in GLP-1-producing L-cells compared to other intestinal cell types. SCFAs raised intracellular calcium in L-cells, triggering hormone release.
The physiological significance was confirmed by knockout experiments. Mice lacking FFAR2 or FFAR3 showed reduced GLP-1 secretion both in vitro and in vivo, with a parallel impairment of glucose tolerance. In other words, removing the bacterial metabolite sensors on L-cells broke the connection between gut bacteria and insulin regulation.
This pathway creates a direct link between dietary fiber intake, gut bacterial composition, and metabolic health. A high-fiber diet feeds fiber-fermenting bacteria, which produce more SCFAs, which stimulate more GLP-1, which improves insulin secretion and reduces appetite. A low-fiber diet starves these bacteria, reduces SCFA production, and weakens the incretin response.
SCFAs Also Drive PYY and Other Peptides
Christiansen and colleagues extended this work using an isolated perfused rat colon preparation in 2018.[3] They found that SCFAs stimulate peptide YY (PYY) release from colonic L-cells, with propionate being the most potent trigger. PYY is the "I'm done eating" signal that reduces appetite and slows gut motility.
The colon perfusion model allowed precise control of SCFA concentrations and eliminated confounding variables present in whole-animal studies. The results confirmed that SCFAs act locally on colonic L-cells, not through systemic circulation or neural reflexes.
Secondary bile acids provide a second bacterial-dependent pathway. Gut bacteria transform primary bile acids (produced by the liver) into secondary bile acids like deoxycholic acid and lithocholic acid. These secondary bile acids activate the TGR5 receptor on L-cells, which increases intracellular cAMP and promotes GLP-1 secretion. This means gut bacteria influence GLP-1 release through at least two independent molecular mechanisms: SCFA/FFAR2 and bile acid/TGR5.
For a deeper look at how gut bacteria influence GLP-1 secretion, see the sibling article.
Direction 2: Peptide Hormones to Bacteria
The communication runs in the other direction as well. GLP-1 receptor agonists do not just respond to the microbiome; they reshape it.
A 2025 systematic review by Gofron and colleagues analyzed the evidence from multiple studies on how GLP-1 analogs and agonists alter gut microbiome composition.[1]
Key findings across the reviewed studies:
- Akkermansia muciniphila increased with GLP-1 receptor agonist treatment. This mucin-degrading bacterium is associated with improved gut barrier function, reduced inflammation, and better metabolic profiles.
- Bacteroides species increased, a genus generally associated with better metabolic homeostasis.
- Pro-inflammatory taxa decreased, correlating with reduced intestinal inflammation.
- Microbial diversity and richness generally improved during GLP-1 receptor agonist therapy.
The mechanisms behind these shifts are not fully established, but several pathways are plausible. GLP-1 receptor agonists slow gastric emptying and alter gut transit time, which changes the nutrient environment that bacteria experience. They also reduce systemic inflammation, which can affect gut barrier integrity and microbial composition. And the weight loss itself, which changes dietary intake patterns, likely contributes.
The bidirectional nature of this relationship creates a potential feedback loop: GLP-1 drugs increase beneficial bacteria that produce more SCFAs, which stimulate more endogenous GLP-1 release, which further supports metabolic improvements. This positive feedback loop has not been proven in humans but is consistent with the available data. It may also partially explain why some individuals respond better to GLP-1 drugs than others: baseline microbiome composition could amplify or dampen the drug's effects.
Direction 3: Bacterial Antimicrobial Peptides
The third arm of this system is the most recently characterized and the most surprising in scale. Gut bacteria do not just produce metabolites that affect host peptides. They produce their own peptides that shape the microbial community itself.
Santos-Junior and colleagues published the most comprehensive survey to date in Cell in 2024.[6] Using machine learning trained on 63,410 metagenomes and 87,920 prokaryotic genomes, they identified 863,498 unique antimicrobial peptides (AMPs) produced by bacteria across environmental and host-associated habitats.
To validate their computational predictions, the team synthesized 100 candidate AMPs and tested them against clinically relevant drug-resistant pathogens and human gut commensal bacteria. The synthesized peptides showed activity against both pathogenic and commensal species, confirming that the microbiome is not just a passive community but an actively peptide-producing ecosystem that uses these molecules to compete, communicate, and establish territorial control.
The implications for the gut-peptide axis are profound. Microbial AMPs help determine which bacterial species survive in the gut, which in turn determines what metabolites (SCFAs, bile acids, neurotransmitters) are produced, which in turn determines what host peptide hormones are released. The antimicrobial peptide layer adds a previously invisible regulatory mechanism underneath the metabolite-to-hormone pathway.
Where GLP-1 Drugs Meet the Microbiome in the Brain
The microbiome-gut-peptide axis does not stop at the gut wall. The peptide signals it generates reach the brain and directly affect feeding behavior.
McMorrow and colleagues showed in 2025 that GLP-1 and GIP receptor agonists rapidly inhibit AgRP neurons in the hypothalamic arcuate nucleus, the brain's primary hunger-promoting circuit.[4] The magnitude of AgRP neuron inhibition was proportional to the reduction in food intake, and dual GIP+GLP-1 agonism produced stronger inhibition than either peptide alone.
Connecting this to the microbiome: bacterial SCFAs stimulate GLP-1 release from L-cells (Direction 1). That GLP-1, whether endogenous or pharmacological, travels to the brain and silences hunger neurons. Meanwhile, the GLP-1 drugs reshape the gut microbiome (Direction 2), potentially increasing SCFA-producing bacteria that further boost endogenous GLP-1 release. And the bacterial antimicrobial peptides (Direction 3) police which bacteria are present to produce those SCFAs in the first place. Beutler's 2026 review of GLP-1 physiology along the gut-brain axis synthesized these pathways into a unified framework.[5]
The full circuit runs: fiber to bacteria to SCFAs to L-cells to GLP-1 to brain to appetite to food choices to fiber intake. Each node can be intervened upon, and each intervention ripples through the system.
What This Means for Treatment
The three-way nature of the microbiome-gut-peptide axis has practical implications:
Individual variation in drug response. If baseline microbiome composition influences how much endogenous GLP-1 a person produces and how responsive their L-cells are to SCFAs, then two patients taking the same dose of semaglutide may have different outcomes partly because of their gut bacteria. Personalized microbiome profiling before prescribing GLP-1 drugs is not yet clinical practice, but the biological rationale is accumulating.
Dietary fiber as a drug enhancer. If SCFAs amplify the incretin response, then dietary fiber intake during GLP-1 therapy is not just generally healthy; it may specifically enhance drug efficacy by feeding the bacteria that produce the metabolites that boost the pathway the drug targets.
Probiotics and prebiotics as adjuncts. Specific bacterial strains that produce high levels of SCFAs or secondary bile acids could theoretically be used as adjuncts to GLP-1 therapy. This is speculative, but several research groups are investigating the concept.
Antibiotic disruption risk. Broad-spectrum antibiotics that disrupt gut bacterial communities could weaken the endogenous SCFA-to-GLP-1 pathway, potentially reducing the effectiveness of metabolic interventions that depend on this axis.
The Bottom Line
The microbiome-gut-peptide axis is a three-way communication system in which gut bacteria produce metabolites (SCFAs, bile acids) that trigger peptide hormone release from intestinal cells; peptide hormones and their pharmacological analogs reshape microbiome composition; and bacterial antimicrobial peptides regulate which microbial species survive to produce those metabolites. This bidirectional, self-reinforcing system connects dietary fiber intake to insulin secretion, appetite regulation, and brain feeding circuits, with implications for understanding individual variation in drug responses and optimizing metabolic therapies.